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Targeting the IGF-1R: the tale of the
tortoise and the hare
Caitrin Crudden 1, Ada Girnita 1,2 and Leonard Girnita 1*
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The insulin-like growth factor type 1 receptor (IGF-1R) plays a key role in the development
and maintenance of cancer. Since the first links between growth factor receptors and
oncogenes were noted over three decades ago, targeting the IGF-1R has been of great
interest. This review follows the progress from inception through intense pharmaceutical
development, disappointing clinical trials and recent updates to the signaling paradigm.
In light of major developments in signaling understanding and activation complexities,
we examine reasons for failure of first line targeting approaches. Recent findings include
the fact that the IGF-1R can signal in the absence of the ligand, in the absence of
kinase activity, and utilizes components of the GPCR system. With recognition of the
unappreciated complexities that this first wave of targeting approaches encountered, we
advocate re-recognition of IGF-1R as a valid target for cancer treatment and look to future
directions, where both research and pharmaceutical strengths can lend themselves to
finally unearthing anti-IGF-1R potential.
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The Race Begins
The Tortoise Starts Slowly: Research Interest Develops
In 1983, two independent groups published their observations of sequence homology between an
oncogene (Simian sarcoma virus oncogene, v-sis) and the platelet-derived growth factor (PDGF) (1,
2). Subsequently, numerous cellular oncogenes began to be described to be homologs of growth
factors, growth factor receptors or of molecules within their signaling cascades: gp55, Bovine
papilloma virus, SV40T antigen, among others. Orchestrating unrestricted cellular proliferation,
it makes sense that oncogenes are found in the driving seat of cellular growth. Investigations
and hypotheses that tyrosine kinase growth factor receptors (RTKs) were intimately involved in
tumorigenesis and malignancy began to gain weight. The late eighties and early nineties seen
research interest grow in this area, as multiple labs studied the PDGF-R and in particular the
Insulin-like growth factor-1 receptor (IGF-1R) systems in in vitro models of human malignancies,
starting with breast cancer (3, 4) and then extending to lung (5), prostate (6), bladder (7), and
others (8–10).
The Hare Shows Interest: R-Cells
The pivotal discovery in 1993 that mouse embryonic fibroblasts derived from embryos with a
targeted disruption (homologous recombination) of the IGF-1R genes, named R-cells (11), were
refractory to transformation, set of a tidal wave of excitement in the field of cancer therapeutics. Not
only were these cells unable to be transformed by a panel of cellular oncogenes (SV40 T antigen (11),
activated H-Ras (12), Raf, bovine papilloma virus (13) but importantly, the loss of this receptor had
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little effect on the cells normal in vitro growth (10% FBS). Mouse
embryonic fibroblasts generated fromwildtype littermates, as well
as R-cells with the IGF-1R reinserted restored the transformation
potential (14, 15). Animal models further propelled this wave,
wherein mice and rat models given antisense IGF-1R strategies
considerably decreased or abolished in vivo tumor growth yet had
very little overall toxicity (16, 17).
The Hare’s Sprint: Pharmaceutical Development
and Clinical Trials
As antisense strategies do not work in humans, several approaches
were undertaken in the late 1990s to target the IGF-1R in anti-
cancer therapeutics, and with strong pre-clinical evidence multi-
ple trials commenced. Over 30 drug candidates were developed
and numerous clinical trials commenced (for current and reg-
ularly updated numbers see ClinicalTrials.gov) (18) as the IGF-
1R became one of the most intensively investigated molecular
targets in oncology. The therapeutics shared the common aim of
inhibiting the kinase signaling cascade activated by the IGF-1R
(Figure 1A), either by (i) prevention of ligand:receptor interac-
tion e.g., through upregulation of the IGFBPs the natural IGF
inhibitors (19), IGFs peptide analogs (20), or receptor/ligand
blocking antibodies (21, 22), or (ii) IGF-1R signaling inhibition
through e.g., small molecule tyrosine kinase inhibitors (23–26)
(Figure 1B) Whilst most trials reported drugs to be well toler-
ated, actual clinical response was limited to a few cancer types
(Ewing’s sarcoma, non-small cell lung cancer), not enough to
maintain pharmaceutical interest. Overall, phase III trials were
disappointing and agents were abruptly shelved [For in depth
reviews of clinical trial results see (18, 23, 27–29)].
The Hare Looses Interest and Takes a Nap:
Why did the Trials Fail?
Many have postulated the reasons why anti-IGF-1R agents failed
to live up to their hype (reviewed in (18, 23, 28, 29) (Figure 2).
Whilst specific mutation of the IGF-1R is rarely reported in the
literature, a large proportion of cancers carry a PI3K mutation
(or PTEN deletion), constitutively activating Akt. In the instance
of constitutive activation of a downstream signaling module such
as Akt, the inhibition of the higher-level receptor will be futile,
and given the rate of occurrence of this mutation across all cancer
types, it is likely that this played a role (Figure 2). In much
the same way, common mutations of the ERK pathway (Ras,
Raf) will similarity constitutively activate the mitogen-activated
protein kinase (MAPK) cascade, irrespective of IGF-1R inhibi-
tion (30) (Figure 2). In 2009, the importance of Insulin receptor
substate-1 (IRS-1) was reported: in cells where IRS-1 is absent
e.g., hematopoietic cells, IGF-1R stimulation leads to very little
mitogenic signal activation or can actually induce differentia-
tion, rendering IGF-1R targeting in these instances useless (31).
Recently added to this list, is the investigation of plasma IGF-
1R in cancer patients (32): anti-IGF-1R antibodies sequestered by
circulating IGF-1R in the plasma could diminish any proposed
therapeutic effect on cancer cells (Figure 2). Another important
consideration is the close relationship between the IGF-1R and
FIGURE 1 | Targeting the IGF-1R. (A) Working model used to design agents
targeting the IGF-1R: linear activation of all downstream signaling pathways
triggered by ligand binding to the receptor and intrinsic kinase activation. Briefly:
Ligand binding induces auto-phosphorylation of the receptor. This activated
confirmation in turn activates two main downstream signaling cascades;
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K),
ultimately leading to the biological effects of protein synthesis, cell survival, cell
cycle progression, and proliferation. (B) IGF-1R targeting strategies: Two main
approaches were taken to inhibit IGF-1R signaling, either by preventing the
binding of the ligand to the receptor (IGFBPs, IGF1 peptide analogs or
antibodies against the receptor or the ligand) or by blocking the receptor-kinase
activation (small molecule tyrosine kinase inhibitors).
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FIGURE 2 | Reasons for failure of IGF-1R targeting. Summary of
reasons suggested for the failure of IGF-1R targeting strategies:
Constitutive activation of downstream signaling nodules such as Ras and
PI3K drive signaling independent of the receptor. First-line targeted
therapeutics such as blocking antibodies could be sequestered by plasma
IGF-1R and in instances where they do reach the cell membrane, can act
as biased agonists instead of antagonists, still activating a subset of
signaling pathways. Similarly, IGF-1R:IR act as hybrid receptors, capable of
binding natural ligands, activating signaling and likely lie under the radar of
blocking IGF-1R antibodies. Altogether, a lack of biomarkers and
insufficient understanding about the IGF-1R signaling complexities is likely
to be the cause of clinical trial failure.
the Insulin receptor (IR). Many independent groups have demon-
strated that the IR can replace mitogenic signaling in cells with
low IGF-1R, and that the IGF-1R and IR can form hybrid recep-
tors, capable of ligand binding, mitogenic signal activation and
likely lie under the radar of IGF-1R designed antibodies (33–37)
(Figure 2).
Along with cellular complexity outsmarting mono-therapy, it
must be highlighted that the IGF-1R pharmaceutical race was
different fromothers in its patient selection strategy.When viewed
alongside the success stories in RTK therapeutics (e.g., HER2, C-
kit therapeutics), the lack of any sort of patient selection, stratifi-
cation or follow-up biomarker for therapeutic efficacy response
in the case of IGF-1R, could very well have been a reason for
failure. The flourish of excitement that a wonder drug lays within
grasp hid the rational and well accepted need for careful patient
selection. The IGF-1R trials included not only a wide range of
cancer types, but also a broad range of molecular determinants
and pre-trial treatment regimens (18) (Figure 2).
The Tortoise Continues: Major
Advancements in IGF-1R Understanding
Signaling Crosstalk
Whilst the canonical signaling schematics of the IGF-1R depict
a ligand binding induced signaling cascade down through the
MAPK and Akt pathways, it has long been recognized that
intracellular signaling is much more network orientated than
linear (Figure 1A). Indeed, at multiple levels throughout the
canonical pathways, crosstalk to other receptors and other path-
ways can and indeed does occur, and one major outcome of the
clinical trials was to reveal the hidden complexity of the IGF-1R
signaling (Figures 1A,B) (28, 29). At the receptor level, the IGF-
1R can not only form hybrid receptors with the IR (38), but the
EGF-R has also been shown to have direct effects, with depletion
affecting IGF-1R ubiquitination, degradation and signaling (39).
In addition to other RTKs, there has been substantial work on
the interaction with integrins, and their effect on IGF-1 signaling
through RACK1 (40, 41) and SHPS1 and SJP2 (42, 43). Bidi-
rectional crosstalk between the IGF-1R system and extracellular
matrix components, such as SHP2 dephosphorylation of paxillin
and FAK act as part of an integrin deactivation mechanism in cell
migration (44). A system with such multilayered crosstalk and
interaction offers plasticity and resilience to a “one-hit” targeting
strategy.
RNA Pathway Regulation
Alongside the explosion of interest in other aspects of cell biol-
ogy, the non-coding-RNA regulation surrounding and controlling
IGF-1R components is beginning to be pieced together. RNAs
such as microRNAs and long-non-coding RNAs implement a
further level of regulation around signaling pathways. This kind
of regulation is illustrated in other pathways, such as p53 where
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a microRNA feedback circuitry has been identified and impli-
cated in the pathogenesis of B-cell lymphocytic leukemia (45).
Interestingly, RNA transcription resulting from one pathways
activation as a method to regulate the signaling of a second
pathway adds yet more feedback circuitry to the network, and
whilst the relevance of this sort of RNA crosstalk has yet to be
investigated for the IGF-1R, it hints at yet another level of signaling
complexity.
RTK:GPCR Functional Hybrid and the
Appreciation of Biased Signaling
A major recent advancement in IGF-1R biology is the challenge
to the RTK functionality (28, 29). Whilst crosstalk between RTK
and G-protein coupled receptor (GPCR) families have long been
demonstrated and are well accepted (46), the functionality of
the IGF-1R stood to be challenged by the demonstration that it
suffices to fulfill all functional definitions of a GPCR. It was first
reported that IGF-1R dependentMAPK signaling was sensitive to
pertussis toxin, a toxin which uncouples the G-protein Gαi from
its cognate receptor (47). The “mere crosstalk” argument to these
experiments was thrown into dispute with the demonstration that
in 3T3-L1 adipocytes, in basal state, Gαi and Gβ were associated
with the IGF-1R and upon IGF-1 stimulation, Gβ was released
andGαi association increased (48). The second parallel camewith
the demonstration that, in much the same way as in GPCRs, β-
arrestin was shown to be important in signal termination and
receptor internalization at the IGF-1R (49, 50). To complete the
story, in 2012 our lab demonstrated the onlymissing link to define
IGF-1R as a functional RTK:GPCR hybrid: the same mechanism
as in GPCRs for β-arrestin-receptor binding to GRK-dependent
serine-phosphorylated sites (51). The functional GPCR signaling
paradigm of ligand binding resulting in GRK phosphorylation,
β-arrestin recruitment, signal termination and internalization,
and the changeable signaling landscape afforded through biased
agonism have all been demonstrated experimentally for the IGF-
1R (29, 51–53). Altogether this strongly supports the updating
of the IGF-1R from a prototypical RTK to an RTK:GPCR func-
tional hybrid. Implications of such an updating highlight the
evidence of non-tyrosine-kinase signaling and the resultant short-
comings of a tyrosine kinase inhibitor in this system (28, 29)
(Figure 2).
In the field of GPCR biology, the paradigm of biased ago-
nism is now fully accepted and describes the process by which
a ligand:receptor pairing can selectively activate various down-
stream signaling pathways preferentially or to different degrees
(54, 55). In a striking similarity, an established IGF-1R target-
ing antibody, in addition to its intended mechanism of action
(kinase inhibition) acts as an IGF-1R/β-arrestin-biased agonist
(52). Moreover, with identification of the human antimicro-
bial peptide LL-37 as an agonist for the IGF-1R, its ability
to activate only the MAPK cascade and not the Akt cascade
demonstrates this paradigm in action at the IGF-1R once again
(53). The understanding of the functional selectivity of ago-
nist/antagonist binding opens up many more therapeutic pos-
sibilities at the IGF-1R than the “OFF” or “ON” model, but
also many more questions about the true complexity of the IGF
system. It is now clear that the receptor can trigger signaling in
the absence of the ligand (49, 51, 56), in the absence of kinase
activity (56, 57) and be selective towards which pathway it acti-
vates (29, 56).
Unappreciated complexity, through the existence of plasma
IGF-1R, hybrid receptors, pathway crosstalk, GPCR signaling
components, RNA pathway regulation, lack of biomarkers, to
name but a few, swamps the simple anti-IGF-1R targeted therapies
in obvious failure (28, 29). However, the story does not end there.
And whilst the “Hare” may have lost interest and had a nap, there
has always been the “Tortoise”, and basic research on the IGF-1R
has continued in labs across the world. Since the disappointing
clinical trials and industry’s frustration and near abandonment,
academia has slowly unearthed a plethora of novel understandings
of how the IGF-1R signals (29, 36).
The Future: Who will Win the Race?
In the early days of growth factor and oncogene research, in
1988, a 22-year long study commenced following a particularly
interesting group of patients, to investigate the role of IGF-1R
in aging, diabetes and cancer development (58). A population of
Ecuadorian individuals suffering from Laron syndrome, carried
mutations in the growth hormone receptor (GHR) gene which
leads to severe GHR and IGF-1 deficiency. As the dust settled
on the IGF-1R trial disappointments, this study was published
(2011), and the results lent yet more support to the fact that
the underlying hypothesis held true. In Individuals (n= 22) with
severe IGF-1 deficiency due to mutation in the GHR gene, cancer
was not a cause of death in any of the subjects, yet it accounted for
20% of cancer deaths in non-affected relatives (58), furthermore
they exhibited no cases of diabetes, compared to the Ecuadorian
normal 5% level in control relatives. Moreover, a study looking at
centenarians’ offspring, found that they had lower circulating IGF-
1 bioactivity and a lower incidence of cancer (59). The IGF-1R and
cancer link formed a few decades ago from sequence homology
identification and in vitro validation is reinforced once again by
epidemiological studies, which are now coming of age. Despite
failure in our naive targeting attempts, it seems the underlying
truth remains.
All postulations ultimately underline the fact that anti-IGF-
1R therapeutic strategies were overly simplistic and insufficient
to have any grand therapeutic effect given the complexity of the
system. Whilst reductionist box-to-box schematics of signaling
pathways are undeniably useful in the molecular and cell biology
classroom, we must also to be aware that they are impossibly
simplistic. Basic research requires simplistic beginnings, but if we
intend to translate these findings into therapeutics, the limitations
and realistic utility of these simple schemes must be appreciated,
something that may not have been fully realized in the IGF-
1R story.
The future of IGF-1R therapeutics may still lie ahead in much
smarter designed, second/third generation targeting that recog-
nizes and complements the true complexity of the system. To take
advantage of those few success cases within the clinical trials,
research effort into biomarkers will be of critical importance.
Biased agonists, which specifically select a subset of signaling
downstream of a given receptor have come into play largely in
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the field of GPCR therapeutics, the largest therapeutically targeted
biological agents of all drugs in use clinically (60). The true
extent of RNA regulation around the IGF-1R system is being built
currently, and may yield many more alterations and targets. And
importantly, lessons learnt from targeted therapeutics across the
tumor biology arena, teach us the pitfalls of mono-targeting and
so it is very likely IGF-1R targeted therapeutic success lies in a
multiple targeted approach and overall system destabilization, or
multi-modality treatment.
With the combination of academia’s unearthing of the
true signaling complexities, and pharmaceutical industry’s drug
development and trial expertise, we may just witness a re-
awakening of shared interest and a re-writing of the tale, and just
maybe the Tortoise and the Hare will finish the race together.
Acknowledgments
Research support: Swedish Research Council, Swedish Cancer
Society, Children Cancer Society, Crown Princess Margareta’s
Foundation for the Visually Impaired, Welander Finsen Foun-
dation, King Gustaf V Jubilee Foundation, Stockholm Cancer
Society, the Stockholm County and Karolinska Institutet.
References
1. Waterfield MD, Scrace GT, Whittle N, Stroobant P, Johnsson A, Wasteson A,
et al. Platelet-derived growth factor is structurally related to the putative trans-
forming protein p28sis of simian sarcoma virus.Nature (1983) 304(5921):35–9.
doi:10.1038/304035a0
2. Doolittle RF, Hunkapiller MW, Hood LE, Devare SG, Robbins KC, Aaron-
son SA, et al. Simian sarcoma virus onc gene, v-sis, is derived from the
gene (or genes) encoding a platelet-derived growth factor. Science (1983)
221(4607):275–7. doi:10.1126/science.6304883
3. Peyrat JP, Bonneterre J, Dusanter-Fourt I, Leroy-Martin B, Djiane J, Demaille
A. Characterization of insulin-like growth factor 1 receptors (IGF1-R) in human
breast cancer cell lines. Bull Cancer (1989) 76(3):311–9.
4. De Leon DD, Wilson DM, Powers M, Rosenfeld RG. Effects of insulin-like
growth factors (IGFs) and IGF receptor antibodies on the proliferation of
human breast cancer cells. Growth Factors (1992) 6(4):327–36. doi:10.3109/
08977199209021544
5. Kaiser U, Schardt C, Brandscheidt D, Wollmer E, Havemann K. Expression
of insulin-like growth factor receptors I and II in normal human lung and
in lung cancer. J Cancer Res Clin Oncol (1993) 119(11):665–8. doi:10.1007/
BF01215985
6. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor
I: action and receptor characterization in human prostate cancer cell lines.
Prostate (1993) 22(3):243–52. doi:10.1002/pros.2990220307
7. Iwamura M, Ishibe M, Sluss PM, Cockett AT. Characterization of insulin-like
growth factor I binding sites in human bladder cancer cell lines.Urol Res (1993)
21(1):27–32. doi:10.1007/BF00295188
8. Minniti CP, Helman LJ. IGF-II in the pathogenesis of rhabdomyosarcoma: a
prototype of IGFs involvement in human tumorigenesis. Adv Exp Med Biol
(1993) 343:327–43. doi:10.1007/978-1-4615-2988-0_32
9. Reiss K, Porcu P, Sell C, Pietrzkowski Z, Baserga R. The insulin-like growth
factor 1 receptor is required for the proliferation of hemopoietic cells.Oncogene
(1992) 7(11):2243–8.
10. Martin DM, Yee D, Feldman EL. Gene expression of the insulin-like growth
factors and their receptors in cultured human retinal pigment epithelial cells.
Brain Res Mol Brain Res (1992) 12(1–3):181–6. doi:10.1016/0169-328X(92)
90082-M
11. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40
large tumor antigen is unable to transformmouse embryonic fibroblasts lacking
type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A (1993)
90(23):11217–21. doi:10.1073/pnas.90.23.11217
12. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, et al.
Effect of a null mutation of the insulin-like growth factor I receptor gene on
growth and transformation of mouse embryo fibroblasts. Mol Cell Biol (1994)
14(6):3604–12.
13. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth?
Cancer Res (1995) 55(2):249–52.
14. Coppola D, Ferber A, Miura M, Sell C, D’Ambrosio C, Rubin R, et al. A
functional insulin-like growth factor I receptor is required for the mitogenic
and transforming activities of the epidermal growth factor receptor. Mol Cell
Biol (1994) 14(7):4588–95.
15. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer
(2003) 107(6):873–7. doi:10.1002/ijc.11487
16. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth
inhibition of human melanoma cells in nude mice by antisense strategies to the
type 1 insulin-like growth factor receptor. Cancer Res (1994) 54(18):4848–50.
17. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, et al.
Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth
factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-
type tumors. Cancer Res (1994) 54(8):2218–22.
18. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor
inhibitors in oncology: early clinical trial results and future directions.Oncogene
(2009) 28(34):3009–21. doi:10.1038/onc.2009.172
19. Ren SG, Ezzat S, Melmed S, Braunstein GD. Somatostatin analog induces
insulin-like growth factor binding protein-1 (IGFBP-1) expression in human
hepatoma cells. Endocrinology (1992) 131(5):2479–81. doi:10.1210/en.131.5.
2479
20. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga
R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of
insulin-like growth factor 1. Cancer Res (1993) 53(5):1102–6.
21. Rohlik QT, Adams D, Kull FC Jr, Jacobs S. An antibody to the receptor
for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue
culture. Biochem Biophys Res Commun (1987) 149(1):276–81. doi:10.1016/
0006-291X(87)91635-4
22. Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1
receptor suppresses growth of human rhabdomyosarcoma and down-regulates
p34cdc2. Cancer Res (1994) 54(21):5531–4.
23. Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol (2013)
228(4):675–9. doi:10.1002/jcp.24217
24. Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A,
et al. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-
1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci (2008)
49(6):2337–42. doi:10.1167/iovs.07-0819
25. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolig-
nans as inhibitors of the insulin-like growth factor-1 receptor and malig-
nant cell growth. Cancer Res (2004) 64(1):236–42. doi:10.1158/0008-5472.
CAN-03-2522
26. Buck E, Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the
treatment of cancer. Expert Opin Investig Drugs (2011) 20(5):605–21. doi:10.
1517/13543784.2011.558501
27. Chen HX, Sharon E. IGF-1R as an anti-cancer target – trials and tribulations.
Chin J Cancer (2013) 32(5):242–52. doi:10.5732/cjc.012.10263
28. Crudden C, Ilic M, Suleymanova N, Worrall C, Girnita A, Girnita L. The
dichotomy of the insulin-like growth factor 1 receptor: RTK and GPCR: friend
or foe for cancer treatment? Growth Horm IGF Res (2015) 25(1):2–12. doi:10.
1016/j.ghir.2014.10.002
29. Girnita L, Worrall C, Takahashi SI, Seregard S, Girnita A. Something old,
something new and something borrowed: emerging paradigm of insulin-like
growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci
(2014) 71(13):2403–27. doi:10.1007/s00018-013-1514-y
30. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S,
et al. Feedbackmechanisms promote cooperativity for smallmolecule inhibitors
of epidermal and insulin-like growth factor receptors. Cancer Res (2008)
68(20):8322–32. doi:10.1158/0008-5472.CAN-07-6720
31. Baserga R. The insulin receptor substrate-1: a biomarker for cancer? Exp Cell
Res (2009) 315(5):727–32. doi:10.1016/j.yexcr.2008.09.017
Frontiers in Endocrinology | www.frontiersin.org April 2015 | Volume 6 | Article 645
Crudden et al. Targeting the IGF-1R
32. Xu JW, Wang TX, You L, Zheng LF, Shu H, Zhang TP, et al. Insulin-like growth
factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels
associated with TNM stage of pancreatic cancer. PLoS One (2014) 9(3):e92847.
doi:10.1371/journal.pone.0092847
33. Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R. Insulin/IGF-I hybrid
receptors play amajor role in IGF-I signaling in thyroid cancer.Biochimie (1999)
81(4):403–7. doi:10.1016/S0300-9084(99)80088-1
34. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi
Y, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpres-
sion in breast cancers leads to insulin/IGF-I hybrid receptor overexpression:
evidence for a second mechanism of IGF-I signaling. Clin Cancer Res (1999)
5(7):1935–44.
35. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin
receptor isoformA, a newly recognized, high-affinity insulin-like growth factor
II receptor in fetal and cancer cells.Mol Cell Biol (1999) 19(5):3278–88.
36. Scotlandi K, Belfiore A. Targeting the insulin-like growth factor (IGF) system
is not as simple as just targeting the type 1 IGF receptor. American Soci-
ety of Clinical Oncology Educational Book/ASCO American Society of Clinical
Oncology Meeting. Alexandria: American Society of Clinical Oncology (2012).
p. 599–604.
37. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I
receptors in human cancer. Curr Pharm Des (2007) 13(7):671–86. doi:10.2174/
138161207780249173
38. Delcourt N, Bockaert J, Marin P. GPCR-jacking: from a new route in RTK
signalling to a new concept in GPCR activation. Trends Pharmacol Sci (2007)
28(12):602–7. doi:10.1016/j.tips.2007.09.007
39. Riedemann J, TakiguchiM, SohailM,MacaulayVM.TheEGF receptor interacts
with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res
Commun (2007) 355(3):707–14. doi:10.1016/j.bbrc.2007.02.012
40. Kiely PA, O’Gorman D, Luong K, Ron D, O’Connor R. Insulin-like growth
factor I controls a mutually exclusive association of RACK1 with protein phos-
phatase 2A and beta1 integrin to promote cell migration. Mol Cell Biol (2006)
26(11):4041–51. doi:10.1128/MCB.01868-05
41. Kiely PA, Sant A, O’Connor R. RACK1 is an insulin-like growth factor 1 (IGF-
1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation
and protection from cell death. J Biol Chem (2002) 277(25):22581–9. doi:10.
1074/jbc.M201758200
42. Ling Y, Maile LA, Clemmons DR. Tyrosine phosphorylation of the beta3-
subunit of the alphaVbeta3 integrin is required for membrane association of
the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like
growth factor I receptor.Mol Endocrinol (2003) 17(9):1824–33. doi:10.1210/me.
2003-0143
43. Maile LA, Badley-Clarke J, Clemmons DR. The association between integrin-
associated protein and SHPS-1 regulates insulin-like growth factor-I receptor
signaling in vascular smooth muscle cells. Mol Biol Cell (2003) 14(9):3519–28.
doi:10.1091/mbc.E03-04-0239
44. Manes S, Mira E, Gomez-Mouton C, Zhao ZJ, Lacalle RA, Martinez AC.
Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase
in regulation of cell motility.Mol Cell Biol (1999) 19(4):3125–35.
45. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, et al.
Association of a microRNA/TP53 feedback circuitry with pathogenesis and
outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 305(1):59–67.
doi:10.1001/jama.2010.1919
46. NatarajanK, BerkBC.Crosstalk coregulationmechanisms ofGprotein-coupled
receptors and receptor tyrosine kinases. Methods Mol Biol (2006) 332:51–77.
doi:10.1385/1-59745-048-0:51
47. Luttrell LM, van Biesen T, Hawes BE, Koch WJ, Touhara K, Lefkowitz RJ. G
beta gamma subunits mediate mitogen-activated protein kinase activation by
the tyrosine kinase insulin-like growth factor 1 receptor. J Biol Chem (1995)
270(28):16495–8. doi:10.1074/jbc.270.28.16495
48. Dalle S, Ricketts W, Imamura T, Vollenweider P, Olefsky JM. Insulin and
insulin-like growth factor I receptors utilize different G protein signaling
components. J Biol Chem (2001) 276(19):15688–95. doi:10.1074/jbc.
M010884200
49. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A, et al. Beta-
arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and
cell cycle progression. J Biol Chem (2007) 282(15):11329–38. doi:10.1074/jbc.
M611526200
50. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ, et al. {beta}-
Arrestin is crucial for ubiquitination and down-regulation of the insulin-like
growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol
Chem (2005) 280(26):24412–9. doi:10.1074/jbc.M501129200
51. Zheng H, Worrall C, Shen H, Issad T, Seregard S, Girnita A, et al. Selective
recruitment of G protein-coupled receptor kinases (GRKs) controls signaling
of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A (2012)
109(18):7055–60. doi:10.1073/pnas.1118359109
52. Zheng H, Shen H, Oprea I, Worrall C, Stefanescu R, Girnita A, et al. beta-
Arrestin-biased agonism as the central mechanism of action for insulin-like
growth factor 1 receptor-targeting antibodies in Ewing’s sarcoma. Proc Natl
Acad Sci U S A (2012) 109(50):20620–5. doi:10.1073/pnas.1216348110
53. Girnita A, Zheng H, Gronberg A, Girnita L, Stahle M. Identification of the
cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor
receptor. Oncogene (2012) 31(3):352–65. doi:10.1038/onc.2011.239
54. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: bias-
ing seven-transmembrane receptors. Nat Rev Drug Discov (2010) 9(5):373–86.
doi:10.1038/nrd3024
55. Wisler JW, Xiao K, Thomsen AR, Lefkowitz RJ. Recent developments in biased
agonism. Curr Opin Cell Biol (2014) 27:18–24. doi:10.1016/j.ceb.2013.10.008
56. Vasilcanu R, Vasilcanu D, Sehat B, Yin S, Girnita A, Axelson M, et al. Insulin-
like growth factor type-I receptor-dependent phosphorylation of extracellular
signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced
by picropodophyllin.Mol Pharmacol (2008) 73(3):930–9. doi:10.1124/mol.107.
040014
57. Perrault R, Wright B, Storie B, Hatherell A, Zahradka P. Tyrosine kinase-
independent activation of extracellular-regulated kinase (ERK) 1/2 by the
insulin-like growth factor-1 receptor. Cell Signal (2011) 23(4):739–46. doi:10.
1016/j.cellsig.2010.12.008
58. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia
F, Cheng CW, et al. Growth hormone receptor deficiency is associated with
a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci
Transl Med (2011) 3(70):70ra13. doi:10.1126/scitranslmed.3001845
59. Vitale G, Brugts MP, Ogliari G, Castaldi D, Fatti LM, Varewijck AJ, et al. Low
circulating IGF-I bioactivity is associated with human longevity: findings in
centenarians’ offspring. Aging (2012) 4(9):580–9.
60. Przydzial MJ, Bhhatarai B, Koleti A, Vempati U, Schurer SC. GPCR ontology:
development and application of a G protein-coupled receptor pharmacol-
ogy knowledge framework. Bioinformatics (2013) 29(24):3211–9. doi:10.1093/
bioinformatics/btt565
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Crudden, Girnita and Girnita. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org April 2015 | Volume 6 | Article 646
